Sangamo will regain full rights to giroctocogene fitelparvovec, a gene therapy candidate for hemophilia A, after Pfizer ended ...
Hosted on MSN58m
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback